Grace Therapeutics, Inc.
GRCE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001444192
In the last 90 days, Grace Therapeutics, Inc. insiders filed 5 open-market purchases and 0 sales; 33 institutions reported holding it in 13F filings for Q2 2026, worth $8.74M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Grace Therapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 10 | 9 | −1 |
| Shares | 127.3K | 93.3K | −34.0K (−26.7%) |
| Value | $108.2K | $53.1K | −$55.1K (−50.9%) |
New holders (2)
Institutions that held Grace Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 24,288 | $14.0K | 0.00% |
| Citadel Advisors LLC | 17,826 | $10.0K | 0.00% |
Sold out (3)
Institutions that held Grace Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Susquehanna International Group, LLP | 25,962 | $22.0K |
| Virtu Financial LLC | 19,715 | $17.0K |
| Toronto Dominion Bank | 57 | $0 |